California NanoSystems Institute
CNSI
Text Size: A A A A

Jenny Kim, Ph.D., M.D.

   
Associate Professor, Medicine, Dermatology
Member, California NanoSystems Institute

Education:
Degrees:
Ph.D., UCLA, 2001
M.D., UCLA School of Medicine, 1991

Certifications:
Certifications:
1999 American Board of Dermatology

Education:
Fellowships:
1993 - 1995 UCLA School of Medicine
Fellowship:
1999 - 2000 UCLA School of Medicine
Internship:
1999 - 2000 Harbor - UCLA Medical Center, Mohs Micrographic Surgery
Residency:
1995 - 1999 UCSF Department of Dermatology
1992 - 1993 Harbor - UCLA Medical Center

Contact Information:
Email Address: jekim@mednet.ucla.edu
Work Email Address: jekim@mednet.ucla.edu
Mailing Address: Division of Dermatology
52-121 Center for the Health Sciences
UCLA School of Medicine
Los Angeles, CA 90095
UNITED STATES
Home Page: http://www.uclahealth.org/JennyKim
Fax Number: (310) 206-9878
Work Phone Number: (310) 825-5420
(310) 825-6911 Work
Research Interests:

Granulysin is an endogenous antimicrobial peptide found in human T and NK cells. We have found in our laboratory that a short synthetic granulysin peptide can kill cutaneous pathogen, Propionibacterium acnes, a microbe that is involved in the pathogenesis of acne. We are using the Vault nanocapsules, developed in Dr. Leonard Rome’s laboratory to make multiple copies of granulysin peptides which can be delivered topically for the treatment of acne and other cuatneous infectious and inflammatory conditions. In addition, while developing better ways to deliver granulysin peptides through skin, we found that our novel chitosan-alginate nanoparticles have both antimicrobial and anti-inflammatory properties. Moreover, these nanoparticles effectively encapsulate benzoyl peroxide, one of the most common acne therapies, and demonstrate superior therapeutic potential. We plan to work with groups in CNSI to develop nanoparticles to deliver skin therapeutics. Skin is the largest immune organ of our body which manifests many infectious and inflammatory conditions and development of therapeutics using skin models is a relatively quick, visually powerful and inexpensive ways to develop novel therapies which then can be modified and applied to treat systemic ailments as well. I am a dermatologist and immunologist and by interacting with CNSI researchers from other disciplines, such as molecular biology, chemistry, pharmacology, physics, and engineering, I believe that novel topical therapeutics can be developed within CNSI.



Selected Publications:

Cho JS, Zussman J, Donegan NP, Ramos RI, Garcia NC, Uslan DZ, Iwakura Y, Simon SI, Cheung AL, Modlin RL, Kim J, Miller LS, Noninvasive In Vivo Imaging to Evaluate Immune Responses and Antimicrobial Therapy against Staphylococcus aureus and USA300 MRSA Skin Infections, J Invest Dermatol, 2011, 131 (4), 907-15.
Zussman J, Abhout J, Kim J, Vitamins and Photoaging: Do Scientific Evidence Support their Data, J Am Acad Dermatol. , 2010, 63 (3), 507-25.
Kim J, Acne vaccines: therapeutic option for the treatment of acne vulgaris?, Journal of Investigative Dermatology, 2009, 128 (10), 2353-4.
Jalian HR, Liu PT, Kanchanapoomi M, Legaspi A, Modlin RL, Kim J, All-trans retinoic acid downregulates Propionibacterium acnes induced matrix metalloproteinase-1,9 and upregulates tissue inhibitors of metalloproteinase-1 in human monocytes, Journal of Investigative Dermatology, 2008, 128, 2777-82.
Liu PT, Phan J, Tang D, Kanchanapoomi M, Hall B, Krutzik SR, Kim J, CD209+ macrophages mediate host defense against Propionibacterium acnes, Journal of Immunology, 2008, 180 (7), 4919-23.
Greco, J, Soriano S, Lask GP, Kim J, Combination Treatment with Broadband Light and Erbium-Doped Yttrium Aluminium Garnet MicroLaser Peel for Photoaged Skin: Case Report of Four Patients, Dermatol Surg, 2008, 34 (11), 1603-8.
Ko CJ, Kim J, Phan J, Binder SW, Bcl-2-positive epidermal dendritic cells in inverted follicular keratoses but not squamous cell carcinomans or Seborrheic keratoses, J Cutaneous Pathology, 2006, 33 (7), 498-501.
McInturff J, Kim J., The Role of Toll: How therapies targeting Toll-like Receptors treat skin diseases, Drug Discovery Today:Therapeutic Strategies, 2006, 3 (1), 75-80.
Liu P, Krutzik S, Kim J, Modlin R, Cutting edge: All-trans retinoic acid downregulates Toll-like receptor-2 expression and function, Journal of Immunology, 2005, 174 (5), 2467-2470.
McInturff J, Wang S-J, Machleidt T, Lin R, Oren A, Hertz C, Krutzik S, Hart S, Zeh K, Anderson D, Gallo R, Modlin RL, Kim J, Granulysin-derived Peptides Demonstrate Antimicrobial and Antiinflammatory Activity against Propionibacterium acnes, J Invest Dermatol, 2005, 125, 256-263.
Kim J, Review of the innate immune response in acne vulgaris: Activation of Toll-like receptor 2 in acne triggers inflammatory cytokine responses, Dermatology, 2005, 211 (3), 193-198.
Miller LS, Sorensen OE, Liu PT, Jalian HR, Eshtiaghpour D, Behmanesh BE, Chung W, Stamer TD, Kim J, Sieling PA, Ganz T, Modlin RL, TGF-{alpha} regulates Toll-like receptor expression and function on epidermal keratinocytes, Journal of Immunology, 2005, 174 (10), 6137-6143.
McInturff J, Modlin RL, Kim J, The Role of Toll-like Receptors in the Pathogenesis and Treatment of Dermatological Disease, J Invest Dermatol, 2005, 125, 1-8.
McInturff J, Kim J., The role of Toll-like Receptors in the Pathogenesis of Acne, Seminars in Cutaneous Medicine and Surgery, 2005, 24 (2), 73-78.
Arora T, Liu B, He H, Kim J, Murphy TL, Murphy KM, Modlin RL, Shuai K, Inhibition of Stat-4-mediated Gene Activation by PIASx, Journal of Biological Chemistry, 2003, 278, 21327-21330.
Lee DJ, Van Dyke GS, Kim J, Update on pathogenesis of acne, Curr Opin Pediatr, 2003, 15 (4), 405-410.
Kim J, Ochoa MT, Krutzik S, Takeuchi O, Uematsu S, Legaspi A, Brightbill H, Holland D, Cunliffe WJ, Akira S, Sieling PA, Godowski PJ, Modlin RL, Activation of Inflammatory Cytokine Responses in Acne Occurs through Toll-like Receptor 2, Journal of Immunology, 2002, 169, 1535-1541.
Kim J, Uyemura K, Van Dyke MK, Legaspi A, Presky DH, Rea TH, Shuai K, Modlin RL, A role for IL-12 receptor expression and signal transduction in host defense in leprosy, Journal of Immunology, 2001, 167, 779-786.
Grimes PE, Bhawan J, Kim J, Chiu M, Lask G, Laser resurfacing-induced hypopigmentation: histologic alterations and repigmentation with topical photochemotherapy, Dermatologic Surgery, 2001, 27, 515-520.
Yamauchi PS, Bleharski JR, Uyemura K, Kim J, Sieling PA, Miller A, Brightbill H, Schlienger K, Rea TH, Modlin RL, A role for CD40-CD40 Ligand interactions in the Generation of Type 1 Cytokine Responses in Human Leprosy, Journal of Immunology, 2000, 165, 1506-1512.
Kim J, Beddingfield FC, Lask GP, Non-ablative Facial Resurfacing, Operative Techniques in Oculoplastic, Orbital, and Reconstructive Surgery, 2000, 3, 55-57.
Kim J, Sette A, Rodda S, Southwood S, Mehra V, Oliveros J, Sieling PA, Rea TH, Bloom BR, Modlin RL, Determinants of T-cell Reactivity to the Mycobacterium leprae GroES Homolog, Journal of Immunology, 1997, 159 (1), 335-343.
Kim J, Modlin RL, Moy RL, Dubinett S, McHugh T, Nickoloff BJ, Uyemura K., IL-10 Production in Cutaneous Basal and Squamous Cell Carcinomas: A Mechanism for Evading the Local T Cell Immune Response, Journal of Immunology, 1995, 155 (4), 2240-2247.
Ohmen JD, Hanifin JM, Nickoloff BJ, Rea TH, Wyzykowski R, Kim J, Jullien D, McHugh T, Nassif AS, Chan SC, Modlin RL. , Overexpression of IL-10 in Atopic Dermatitis, Journal of Immunology, 1995, 154 (4), 1956-1963.